Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $10.80

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have received an average rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $10.80.

Separately, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th.

Xeris Biopharma Price Performance

Shares of XERS opened at $8.28 on Wednesday. Xeris Biopharma has a 52 week low of $4.87 and a 52 week high of $10.08. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of 138.00 and a beta of 0.62. The stock has a 50 day moving average of $6.94 and a 200-day moving average of $6.69.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. As a group, analysts forecast that Xeris Biopharma will post 0.12 EPS for the current year.

Insider Buying and Selling

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the sale, the director directly owned 126,500 shares of the company’s stock, valued at approximately $770,385. This represents a 11.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02. Following the sale, the insider owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. The trade was a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 251,500 shares of company stock valued at $1,846,457. Company insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in Xeris Biopharma by 21.8% in the 1st quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock worth $5,072,000 after purchasing an additional 156,483 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Xeris Biopharma by 322.8% during the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after buying an additional 225,602 shares in the last quarter. California State Teachers Retirement System lifted its stake in Xeris Biopharma by 19.3% during the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock valued at $1,046,000 after buying an additional 29,168 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Xeris Biopharma by 12.9% in the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after buying an additional 4,974 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Xeris Biopharma by 59.0% in the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after buying an additional 27,003 shares during the period. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.